Clinical trials: Endocrine System Diseases
Diabetes Mellitus, Type 2
Diabetes Homelessness Medication Support Program in Spanish
This single-arm trial of the Diabetes Homeless Medication Support intervention for Spanish-speaking people (n=12) will test the perception and feasibility of anticipated study procedures.
- Trial name
- DH-Spanish (NCT05819749)
- Testing
- Diabetes Homelessness Medication Support Program in Spanish
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Hennepin Healthcare Research Institute
Type 1 Diabetes
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Introduction: The purpose of the pivotal In Home study is to collect clinical data on the safety and efficacy of the Paradigm LGS System in the actual use environment and by the intended use population.
- Trial name
- ASPIRE (NCT01497938)
- Testing
- Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature, Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes, Sedentary Behavior
Technology Based Sedentary Reduction Intervention in Patients With Type 2 Diabetes
The purpose of this study is to develop and test an 8-week sedentary behavior reduction intervention ("Sit Less" program) for patients with type 2 diabetes.
- Conditions
- Type 2 Diabetes, Sedentary Behavior, Physical Activity
- Trial name
- NCT05691452
- Testing
- Sit Less Program
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Diabetes Mellitus, Leg Injuries
Prosthetic Components and Stability in Amputee Gait
The biomechanics of changing direction while walking has been largely neglected despite its relevancy to functional mobility. In addition, an increased risk of injury can be associated with turning due to a decrease in stability.
- Conditions
- Diabetes Mellitus, Leg Injuries, Traumatic Amputation
- Trial name
- NCT00167778
- Testing
- Transverse plane rotation adaptor pylon, Rigid pylon
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Adrenal Insufficiency
Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to…
- Trial name
- NCT00915343
- Testing
- hydrocortisone (modified release), oral tablet 20 and 5 mg, Hydrocortisone, oral tablet, 10 mg
- Volunteers
- 64 people
- Sponsor
- Shire
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Metformin
- Trial name
- NCT00817778
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Diabetic Foot Ulcer
MIRODERM H2H DFU Study
This study will assess the ability of MIRODERM to heal difficult diabetic foot ulcers within 12 weeks of treatment.
- Trial name
- H2H-DFU (NCT03232333)
- Testing
- Biologic wound graft
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Miromatrix Medical Inc.
Type 2 Diabetes
A Study of LY3437943 in Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of…
- Trial name
- NCT04867785
- Testing
- LY3437943, Dulaglutide
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NCT02632747
- Testing
- Empagliflozin, ramipril
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
This randomized phase II trial is studying bevacizumab, gemcitabine, and cetuximab to see how well they work compared to bevacizumab, gemcitabine, and erlotinib in treating patients with advanced pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00091026
- Testing
- cetuximab, gemcitabine hydrochloride, bevacizumab
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- National Cancer Institute (NCI)
Type 2 Diabetes, Coronary Artery Disease
Effects of Linagliptin on Endothelial Function
This study is planned to evaluate if linagliptin can improve endothelial function in patients with type 2 diabetes mellitus. In addition, the effect of linagliptin on arginine bioavailability ratios and postchallenge glycaemic…
- Trial name
- NCT02350478
- Testing
- Linagliptin
- Where
- Austria
- Volunteers
- 49 people
- Sponsor
- Medical University of Graz
Diabetes Mellitus, Type 2
Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (Linagliptin) (5 mg / once daily) compared to placebo given for 24 weeks as initial combination therapy with pioglitazone 30 mg…
- Trial name
- NCT00641043
- Testing
- Linagliptin + pioglitazone (30 mg)
- Where
- 43 sites in Austria, Greece and 5 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Neoplasms
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
The purpose of this trial is to estimate progression free survival in patients with recurrent or metastatic head and neck cancer that have not received chemotherapy in this setting.
- Trial name
- NCT01057589
- Testing
- Pemetrexed, Cetuximab, Cisplatin
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Cancer of the Pancreas
A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas
This study is being done to determine whether or not addition of the oral medication, pioglitazone to standard chemotherapy, results in improvement of blood tests that measure the body's ability to utilize sugar (glucose and…
- Trial name
- NCT01838317
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Texas Southwestern Medical Center
Pancreatic Cancer
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
The intention of this trial is to determine the maximum tolerated of the treatment combination and to evaluate its safety and efficacy.
- Trial name
- NCT00463840
- Testing
- Oxaliplatin, 5FU, Radiation
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- NYU Langone Health
Type 2 Diabetes Mellitus
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
Primary Objective: To investigate the effects of repeated subcutaneous doses of lixisenatide 20 μg once daily (QD) as compared to liraglutide 1.2 mg QD or 1.8 mg QD in reducing post-prandial plasma glucose (PPG) assessed as area…
- Trial name
- NCT01596504
- Testing
- Lixisenatide (AVE0010), Liraglutide, Insulin Glargine
- Where
- 8 sites in Germany
- Volunteers
- 142 people
- Sponsor
- Sanofi
Obesity
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy…
- Trial name
- NCT01725126
- Testing
- GSK2890457, Metformin, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes
Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes: Outpatient Exercise Protocol
Manually suspending an insulin pump at the beginning of aerobic exercise reduces the risk of exercise-associated hypoglycemia (low blood sugar) in patients with type 1 diabetes (T1D).
- Trial name
- NCT02047643
- Testing
- Computer algorithm to initiate pump suspension
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
Type 1 Diabetes Mellitus
Omega-3 and Vitamin D Supplements in Childhood T1D
The study was conducted in 64 patients with T1D of which 26 had the onset in 2017, and 38 in 2016, 2015 and 2014. All received vitamin D 1000 IU /day since disease's onset.
- Trial name
- NCT03911843
- Testing
- omega-3 supplementation, Vitamin D supplementation
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.